Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 1,000 shares of Atara Biotherapeutics stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $46.31, for a total value of $46,310.00. Following the sale, the chief executive officer now directly owns 812,613 shares in the company, valued at $37,632,108.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Atara Biotherapeutics Inc (ATRA) remained flat at $$41.90 during trading hours on Friday. The stock had a trading volume of 2,974,813 shares, compared to its average volume of 791,481. The firm has a market capitalization of $1,626.80, a price-to-earnings ratio of -10.50 and a beta of 2.59. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $49.90.
A number of analysts have recently issued reports on the company. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price on the stock in a research report on Wednesday, January 3rd. Canaccord Genuity reaffirmed a “positive” rating and set a $70.00 target price (up from $47.00) on shares of Atara Biotherapeutics in a research report on Friday, January 19th. BidaskClub raised Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 13th. Guggenheim assumed coverage on Atara Biotherapeutics in a research report on Thursday. They set a “neutral” rating on the stock. Finally, Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. One analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $33.80.
Large investors have recently bought and sold shares of the stock. Pacific Heights Asset Management LLC acquired a new position in Atara Biotherapeutics in the fourth quarter worth about $453,000. Artal Group S.A. grew its stake in Atara Biotherapeutics by 66.7% in the fourth quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock worth $18,100,000 after purchasing an additional 400,000 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Atara Biotherapeutics in the third quarter worth about $581,000. Nexthera Capital LP acquired a new position in Atara Biotherapeutics in the fourth quarter worth about $5,188,000. Finally, Neuberger Berman Group LLC grew its stake in Atara Biotherapeutics by 15.2% in the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after purchasing an additional 147,061 shares in the last quarter. Institutional investors and hedge funds own 76.88% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics Inc (ATRA) CEO Sells $46,310.00 in Stock” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/17/atara-biotherapeutics-inc-atra-ceo-sells-46310-00-in-stock.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.